GE Healthcare and BioSpring start large-scale European production of oligonucleotides
GE Healthcare in the UK and German oligonucleotide producer, BioSpring, have installed Europe's first automated DNA/RNA synthesizer ÄKTA OligoPilotT 400, at BioSpring's plant in Frankfurt. The OP 400 allows large-scale production of oligos, in the 100g to several kg range. Until now, such large-scale automated synthesizers existed only in the US.
GE Healthcare in the UK and German oligonucleotide producer, BioSpring, have installed Europe's first automated DNA/RNA synthesizer aKTA OligoPilotT 400, at BioSpring's plant in Frankfurt. The OP 400 allows large-scale production of oligos, in the 100g to several kg range. Until now, such large-scale automated synthesizers existed only in the US.
Dr Sylvia Wojczewski, ceo, BioSpring said: "The number of pipeline projects for therapeutic oligos is increasing substantially and several candidates are now in clinical trials, so the need for production of large quantities of highly pure oligos has increased."
"Installation of this aKTA OligoPilot 400 confirms that the oligo market is back on track and moving towards late clinical phases," said Ann O'Hara, general manager, Bioprocess, GE Healthcare. "The European market has been behind the American market in clinical trials for oligonucleotides, so we are pleased to support BioSpring at the centre of driving the region's development of large scale manufacturing."
BioSpring develops and produces oligonucleotides for the therapeutic and diagnostic markets, as well as for research purposes.
GE Healthcare provides a broad range of medical technologies and services including expertise in medical imaging, medical diagnostics, drug discovery, and biopharmaceutical manufacturing technologies.
